Skip to main content

Coronary Drug-Eluting Therapies Data

Confidence to treat every patient, any challenge

Modern PCI means using all the newest data and tools at our disposal to provide the best possible treatment for coronary artery disease (CAD) patients. The latest SYNTAX II results, along with supporting clinical evidence, like the AGENT IDE Trial, show that integrating risk stratification, multidisciplinary collaboration, new tools & techniques, and innovative drug eluting technologies (DET) can lead to better outcomes -- even in the most complex cases.

An AGENT of change for ISR treatment 

Data from the first coronary drug-coated balloon (DCB) study in U.S. met the 1-year primary endpoint and demonstrated low adverse event rates. 

  • Primary endpoint1 met! AGENT DCB showed statistically superior outcomes compared to balloon angioplasty for TLF at 1-year. (17.9% versus 28.6% P= 0.003).
  • The TLF relative risk reduction from using AGENT DCB was approximately 41%.
41%

Read the trial results (PDF)

The latest generation DES plays a role in elevating PCI outcomes

The CONSISTENT CTO2 study showed the use of up-to-date technologies and techniques in opening a CTO, including the use of an everolimus eluting stent with a bioabsorbable polymer, can result in significant quality of life improvements without significant impact on intravascular healing, even in very symptomatic patients with complex lesions.

  • Using the latest PCI technologies and techniques can drive substantial quality of life improvements. 

  • Successful CTO PCI in 91% of patients. 

  • Significant improvement in all SAQ components at 12 months. 

SYNERGY BP Stent and SYNTAX II

SYNTAX II3 examined the outcomes of a PCI strategy focused on utilizing the newest data and tools to provide the best possible treatment for CAD patients. Among the modern tools used in the trial was the SYNERGY Bioabsorbable Polymer (BP) Stent Platform. At the five-year milestone, the trial has demonstrated CABG-like outcomes through modern PCI. Low rates of revascularization, peri-procedural MI, and acute ST suggest that superior tools might help reduce procedure-related complications in multi-vessel diseased patients.

relative risk reduction

SYNERGY’s Everolimus drug and bioabsorbable polymer promote early healing through fast drug elution and freedom from the risks of long-term polymer exposure. 

  • Studied in more than 35,000 patients, addressing the full spectrum of CAD complexity

  • Consistently excellent results, including low ST rates, in large, randomized trials. 

  • Leading in dual antiplatelet therapy (DAPT) studies and indicated for use with HBR patients.

Patients are unique. Shorten DAPT with confidence.

We know every patient needs individualized care. Boston Scientific is leading the way in supporting short DAPT studies with SYNERGY in a variety of patient populations and DAPT durations.

risk reduction

Excellent outcomes in long lesions

EVOLVE 48 Trial: Final 2-year Results

Supports the safety and effectiveness of the SYNERGY XD 48 mm BP Stent for treatment of long lesions.4  

risk reduction

Consistently low ST rates, even in complex patients

SENIOR, EVOLVE 48, CLEAR SYNERGY, EVOLVE XLV, BIO RESORT, SCAAR, Kang Meta-Analysis, EVOLVE II, POEM, BIO-RESORT, EVOLVE LV, ASET, EVOLVE Short DAPT

*MACCE is a composite of all-cause death, stroke, MI, and any repeat revascularization

**Defined as any ischemia-driven target lesion revascularization, target vessel-related myocardial infarction, or cardiac death

†The safety and effectiveness of the SYNERGY BP Stent has not been established in Left Main or bifurcation lesions. Please review the SYNERGY IFU for full instructions on use.

‡Defined as any ischemia-driven target lesion revascularization, target vessel-related myocardial infarction, or cardiac death

1. AGENT IDE Clinical Trial data presented at CRT 2024 by Dr. Robert Yeh.

2. Walsh SJ, Hanratty CG, McEntegart M, Strange JW, Rigger J, Henriksen PA, Smith EJ, Wilson SJ, Hill JM, Mehmedbegovic Z, Chevalier B, Morice MC, Spratt JC. Intravascular Healing Is Not Affected by Approaches in Contemporary CTO PCI: The CONSISTENT CTO Study. JACC Cardiovasc Interv. 2020 Jun 22;13(12):1448-1457. doi: 10.1016/j.jcin.2020.03.032. PMID: 32553333. 

3. The SYNTAX II Trial studied the SYNERGY Bioabsorbable Polymer Stent in patients with either CTO or three vessel disease. The SYNTAX I trial studied the TAXUS Express2 drug eluting stent in patients with either Left Main or three vessel disease. Banning, Adrian, MBBS, MD. Clinical outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 5-year results of the SYNTAX II study. ESC Congress 2021. 

4.  Karmpaliotis, D et al. Catheter Cardiovasc Interv. doi:10.1002/ccd.29798. Clinical data conducted with SYNERGY 48 mm, SYNERGY XD’s predecessor device, which can be used to illustrate SYNERGY XD 48 mm clinical data.